Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Date: June 4, 2026
Time: 9:55 AM – 10:25 AM EDT
A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/presentations. A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation.
About Turn Therapeutics
Turn Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Its lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor currently in development for the treatment of moderate-to-severe atopic dermatitis. This therapy is designed to modulate key inflammatory pathways involved in eczema and other inflammatory dermatological conditions, specifically targeting IL-36 and IL-31, two cytokines that play distinct but interconnected roles in driving chronic skin inflammation and the itch-scratch cycle. GX-03 addresses IL-36 upstream, where epithelial stress and barrier disruption initiate the inflammatory cascade, and IL-31 downstream, where itch signaling perpetuates disease. It is currently being evaluated in a Phase 2 randomized controlled trial, with topline results expected in mid-2026.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260519539083/en/
Investor Relations / Media Contact
Sasha Damouni
Damouni Group LLC
Sasha@damounigroup.com
Source: Turn Therapeutics Inc.